PMID- 37351973
OWN - NLM
STAT- MEDLINE
DCOM- 20230626
LR  - 20230626
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 43
IP  - 7
DP  - 2023 Jul
TI  - Development of Real-world Data-based Medication Instruction Sheet for Acute 
      Myeloid Leukemia Patients Receiving High-dose Cytarabine Consolidation Therapy.
PG  - 3321-3329
LID - 10.21873/anticanres.16508 [doi]
AB  - BACKGROUND/AIM: For quick and accurate monitoring of potential adverse events 
      (AEs) during concurrent chemotherapy, we had previously developed innovative 
      medication instruction sheets (MIS) for a variety of chemotherapy regimens. 
      However, it is still unclear whether these sheets correctly predict the type and 
      time course of the onset and recovery of AEs. Therefore, we monitored AEs in 
      patients with acute myeloid leukemia (AML) receiving high-dose cytarabine 
      (HD-AraC) using the original MIS. PATIENTS AND METHODS: Patients who received 
      HD-AraC following remission induction chemotherapy were included in this study. 
      Data obtained from AE monitoring were evaluated, and the original MIS was 
      modified as appropriate. RESULTS: Among 41 patients, a total of 203 AEs (139 
      non-hematological and 64 hematological) were observed after chemotherapy. By 
      contrast, all but one patient (97.6%) experienced 102 AEs (43 non-hematological 
      and 59 hematological) before chemotherapy. The AEs that appeared after 
      chemotherapy were all predicted items described in the original MIS; however, 
      their onset and duration were not consistent with the predicted data, in which 
      the prediction accuracy was 69.1% for non-hematological AEs and 1.6% for 
      hematological events. Based on these monitoring data, the original MIS was 
      revised, which led to an increase in the prediction accuracy to 94.2% for 
      nonhematological events and 100% for hematological events. CONCLUSION: 
      Preexisting AEs should be considered when preparing MIS for consolidation therapy 
      with HD-AraC. The modified MIS based on AE monitoring exhibited a sufficiently 
      high prediction accuracy.
CI  - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Uchida, Mayako
AU  - Uchida M
AD  - Department of Education and Research Center for Pharmacy Practice, Faculty of 
      Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan; 
      m-uchida@dwc.doshisha.ac.jp.
FAU - Ishida, Shigeru
AU  - Ishida S
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
FAU - Mochizuki, Erika
AU  - Mochizuki E
AD  - Department of Education and Research Center for Pharmacy Practice, Faculty of 
      Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
FAU - Ozawa, Nana
AU  - Ozawa N
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
FAU - Yonemitsu, Hiroko
AU  - Yonemitsu H
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
FAU - Ochiai, Hideki
AU  - Ochiai H
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
FAU - Nakamura, Hanae
AU  - Nakamura H
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
FAU - Kawashiri, Takehiro
AU  - Kawashiri T
AD  - Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of 
      Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
FAU - Kato, Koji
AU  - Kato K
AD  - Department of Medicine and Biosystemic Science, Kyushu University Graduate School 
      of Medical Sciences, Fukuoka, Japan.
FAU - Egashira, Nobuaki
AU  - Egashira N
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
FAU - Akashi, Koichi
AU  - Akashi K
AD  - Department of Medicine and Biosystemic Science, Kyushu University Graduate School 
      of Medical Sciences, Fukuoka, Japan.
FAU - Ieiri, Ichiro
AU  - Ieiri I
AD  - Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 04079A1RDZ (Cytarabine)
SB  - IM
MH  - Humans
MH  - *Cytarabine
MH  - Consolidation Chemotherapy
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - *Leukemia, Myeloid, Acute/drug therapy/etiology
MH  - Remission Induction
OTO - NOTNLM
OT  - Chemotherapy
OT  - acute myeloid leukemia
OT  - adverse events
OT  - high-dose cytarabine consolidation therapy
OT  - medication instruction sheet
EDAT- 2023/06/23 19:11
MHDA- 2023/06/26 06:42
CRDT- 2023/06/23 12:13
PHST- 2023/04/08 00:00 [received]
PHST- 2023/04/24 00:00 [revised]
PHST- 2023/04/25 00:00 [accepted]
PHST- 2023/06/26 06:42 [medline]
PHST- 2023/06/23 19:11 [pubmed]
PHST- 2023/06/23 12:13 [entrez]
AID - 43/7/3321 [pii]
AID - 10.21873/anticanres.16508 [doi]
PST - ppublish
SO  - Anticancer Res. 2023 Jul;43(7):3321-3329. doi: 10.21873/anticanres.16508.